Bionano Genomics Inc. [BNGO] stock Resumed by Oppenheimer analyst, price target now $12

Bionano Genomics Inc. [NASDAQ: BNGO] closed the trading session at $2.66 on 08/19/22. The day’s price range saw the stock hit a low of $2.65, while the highest price level was $3.01. The company report on August 11, 2022 that Bionano Genomics Announces First Publication Using OGM for Detection of Repeat Expansions in CANVAS and Adult-Onset Ataxia.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to evaluate the utility of optical genome mapping (OGM) in the analysis of repeat expansion disorders. Repeat expansion disorders are a class of disorders that impact approximately 1 in 3,000 people and are caused by expansions of short tandem DNA repeats.

Researchers in this study describe how OGM can be adopted as an alternative to Southern blot analysis for the identification of repeat expansions in the RFC1 gene that lead to cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome (CANVAS) and adult-onset ataxia in multiple populations. Individuals with RFC1 (AAGGG)n repeat expansion disorder may present with a spectrum of features including cerebellar ataxia, neuropathy, and vestibular areflexia. Specifically, ataxias are a group of neurodegenerative repeat expansion disorders, characterized by atrophy of the cerebellum that leads to the inability to control balance and coordination. Even though there are many known cerebellar ataxia–causing genes and variations, some adult patients with adult-onset ataxia remain genetically undiagnosed, and studies to identify genetic causes are ongoing.

The stocks have a year to date performance of -11.04 percent and weekly performance of -26.11 percent. The stock has been moved at 30.39 percent over the last six months. The stock has performed 36.41 percent around the most recent 30 days and changed 58.33 percent over the most recent 3-months.

If compared to the average trading volume of 8.22M shares, BNGO reached to a volume of 8923619 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Bionano Genomics Inc. [BNGO]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BNGO shares is $8.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BNGO stock is a recommendation set at 1.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Oppenheimer have made an estimate for Bionano Genomics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 18, 2022. While these analysts kept the previous recommendation, BTIG Research raised their target price to Buy. The new note on the price target was released on June 16, 2021, representing the official price target for Bionano Genomics Inc. stock. Previously, the target price had yet another raise to $1.25, while Ladenburg Thalmann analysts kept a Buy rating on BNGO stock.

The Average True Range (ATR) for Bionano Genomics Inc. is set at 0.32, with the Price to Sales ratio for BNGO stock in the period of the last 12 months amounting to 35.99. The Price to Book ratio for the last quarter was 2.66, with the Price to Cash per share for the same quarter was set at 0.59.

BNGO stock trade performance evaluation

Bionano Genomics Inc. [BNGO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -26.11. With this latest performance, BNGO shares gained by 36.41% in over the last four-week period, additionally plugging by 30.39% over the last 6 months – not to mention a drop of -48.25% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BNGO stock in for the last two-week period is set at 53.67, with the RSI for the last a single of trading hit 47.90, and the three-weeks RSI is set at 55.95 for Bionano Genomics Inc. [BNGO]. The present Moving Average for the last 50 days of trading for this stock 1.94, while it was recorded at 3.15 for the last single week of trading, and 2.43 for the last 200 days.

Bionano Genomics Inc. [BNGO]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Bionano Genomics Inc. [BNGO] shares currently have an operating margin of -428.79 and a Gross Margin at +4.47. Bionano Genomics Inc.’s Net Margin is presently recorded at -402.84.

Return on Equity for this stock declined to -38.92, with Return on Assets sitting at -33.11.

Bionano Genomics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.00 and a Current Ratio set at 7.80.

Bionano Genomics Inc. [BNGO]: Insider Ownership positions

There are presently around $219 million, or 28.70% of BNGO stock, in the hands of institutional investors. The top three institutional holders of BNGO stocks are: BLACKROCK INC. with ownership of 21,021,575, which is approximately 13.046% of the company’s market cap and around 0.30% of the total institutional ownership; VANGUARD GROUP INC, holding 15,634,397 shares of the stock with an approximate value of $41.59 million in BNGO stocks shares; and STATE STREET CORP, currently with $22.38 million in BNGO stock with ownership of nearly 8.944% of the company’s market capitalization.

Positions in Bionano Genomics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 68 institutional holders increased their position in Bionano Genomics Inc. [NASDAQ:BNGO] by around 13,742,024 shares. Additionally, 66 investors decreased positions by around 4,051,890 shares, while 47 investors held positions by with 64,552,969 shares. The mentioned changes placed institutional holdings at 82,346,883 shares, according to the latest SEC report filing. BNGO stock had 26 new institutional investments in for a total of 1,836,124 shares, while 21 institutional investors sold positions of 646,740 shares during the same period.


Please enter your comment!
Please enter your name here